Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Lumakras Falls Short Of Mirati’s Adagrasib In Pancreatic Cancer

Pressure On To Make Most Of Lung Cancer Foothold

Executive Summary

The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.

You may also be interested in...



Amgen NSCLC Data Could Give Lumakras Boost As Competition Looms

Mirati’s adagrasib is expected to win an FDA lung cancer nod, while also showing better data in pancreatic and colorectal cancer, making it more important for Lumakras to show strength in NSCLC.

Amgen Revenue Boosted By COVID-19 Manufacturing, Flat To Down Without It

The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits. 

Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer

While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel